Opiate receptor binding: effects of enzymatic treatments.
D000818:Animals; D001921:Brain / Q000378:metabolism; D002118:Calcium / Q000494:pharmacology; D002498:Centrifugation; D002855:Chromatography, Thin Layer; D002918:Chymotrypsin / Q000494:pharmacology; D002919:Chymotrypsinogen / Q000494:pharmacology; D003851:Deoxyribonucleases / Q000494:pharmacology; D004355:Drug Stability; D004492:Edetic Acid / Q000494:pharmacology; D004798:Enzymes / Q000494:pharmacology*; D005374:Filtration; D066298:In Vitro Techniques; D007981:Levorphanol / Q000494:pharmacology; D008297:Male; D009019:Morphinans; D009270:Naloxone / Q000378:metabolism; D009439:Neuraminidase / Q000494:pharmacology; D010740:Phospholipases / Q000494:pharmacology; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects*; D012260:Ribonucleases / Q000494:pharmacology; D014316:Tritium; D014357:Trypsin / Q000494:pharmacology; D014362:Trypsinogen / Q000494:pharmacology
D004798:Enzymes; D009019:Morphinans; D011955:Receptors, Drug; D014316:Tritium; D007981:Levorphanol; D009270:Naloxone; D014362:Trypsinogen; D002919:Chymotrypsinogen; D004492:Edetic Acid; D003851:Deoxyribonucleases; D010740:Phospholipases; D012260:Ribonucleases; D009439:Neuraminidase; D002918:Chymotrypsin; D014357:Trypsin; D002118:Calcium